26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public comment until 15 September 2021.

The CER announced today that it will assess the comparative clinical effectiveness and value of the following treatments for COVID-19:

• casirivimab/imdevimab (REGEN-COV, Regeneron)
• sotrovimab (GSK and Vir Biotechnology)
• molnupiravir (Merck)
• PF-07321332/ritonavir (Pfizer)
• fluvoxamine (investigator initiated)

Read ICER Announcement